FACSIMILE TRANSMITTAL

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park CA 94025
Telephone: (650) 327-3400
Facsimile Number: (650) 327-3231

Date: May 28, 2003

Arun Chakrabarti

FAX 703 305 3014

From: Pamela Sherwood

Total number of pages, including this cover sheet: 2

****

Attached please find a PTOL-413A Interview Request Form

PTOL-413A (05-03)
Approved for use through xx/xx/xxxx OMB 0651-00xx
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Applicant Initiated Interview Request Form

Application No.: 10/027807 First Named Applicant: Li Gan
Examiner: A. Chakrabarti Art Unit: 1634 Status of Application: Final OA

Tentative Participants:
(1) Arun Chakrabarti (2) Pamela Sherwood
(3) Rebecca Taylor (4)

Proposed Date of Interview: May 29, 2003 **Proposed Time:** 10:00 (AM/PM) PACIFIC TIME

Type of Interview Requested:
(1) [X] Telephonic (2) [ ] Personal (3) [ ] Video Conference

Exhibit To Be Shown or Demonstrated: [X] YES [ ] NO
If yes, provide brief description: Summary in art defining differences between RNAi and antisense; and induction of interferon response by RNAi in mammalian cells.

Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) 103(a)	14-15, 17, 23-25 30, 51, 54-56, 45 52-53	Leptin, Der	[ ]	[ ]	[ ]
(2) 103(a)	19-20	Leptin, Der Petryshyn	[ ]	[ ]	[ ]
(3)			[ ]	[ ]	[ ]
(4)			[ ]	[ ]	[ ]

[ ] Continuation Sheet Attached

Brief Description of Arguments to be Presented:
Invertebrate cells lack interferon response and therefore cannot predict the results of RNAi in mammalian cells, which have an interferon response. RNAi and antisense RNA involve different molecules and mechanisms; one does not obviate the other.
An interview was conducted on the above-identified application on _____.

NOTE:
This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).
This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.

(Applicant/Applicant's Representative Signature) (Examiner/SPE Signature)

CERTIFICATE OF TRANSMISSION			
I hereby certify that this correspondence is being transmitted by facsimile transmission to the United States Patent and Trademark Office on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. Facsimile No.: (703) 305-3014			
Typed or Printed Name	Susan M. Alessi		
Signature	Susan Alessi	Date	May 28, 2003

FACSIMILE TRANSMITTAL
BOZICEVIC, FIELD & FRANCIS LLP

200 Middlefield Road
Suite 200
Menlo Park, California 94025
Telephone (650) 327-3400
Facsimile (650) 327-3231

Date: May 28, 2003

To: **Please deliver to Examiner Arun K. Chakrabarti**
Art Unit 1634, USPTO

Facsimile No.: (703) 305-3014

From: Susan M. Alessi assisting
Pamela J. Sherwood, Ph.D., Reg. No. 36,677

Re: U.S. Patent Application No. 10/027,807
Title: HIGH THROUGHPUT TRANSCRIPTOME AND FUNCTIONAL VALIDATION ANALYSIS
Inventor(s): GAN et al.
Attorney Docket No.: AGYT-013CIP

Message:

- **Transmittal (1 page)**
- **Communication (1 page)**
- **Exhibits (13 pages)**

Please find attached for your phone conference with Pam tomorrow. If there are any problems concerning the transmission for these documents please contact Susan M. Alessi at (650) 833-7714 or Via email at alessi@bozpat.com.

Thank you!

Total number of pages, including this cover sheet: 16

Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission: 16

Application Number	10/027,807
Filing Date	October 19, 2001
First Named Inventor	GAN, LI
Group Art Unit	1634
Examiner Name	CHAKRABARTI, ARUN K.
Attorney Docket Number	AGYT-013CIP

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment / Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Documents
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)

Remarks

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) *(please identify below)*
  1. **Communication**
  2. **Exhibits**
  3. **Fax Cover Sheet**

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	**PAMELA J. SHERWOOD, Reg. No. 36,677**
Signature	Pamela J. Sherwood
Date	**May 28, 2003**

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile filed under 37 C.F.R. §§ 1.6(d) and 1.8(a)(1)(b) addressed to: Commissioner for Patents Commissioner for Patents, Washington, DC 20231 on this date: May 28, 2003

Typed or printed name	Susan M. Alessi		
Signature	Susan Alessi	Date	May 28, 2003

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Communication		
	Attorney Docket No.	AGYT-013CIP
	Confirmation No.	9177
	First Named Inventor	L. Gan
Address to:	Application Number	10/027,807
Assistant Commissioner for Patents	Filing Date	October 19, 2001
Washington, D.C. 20231	Group Art Unit	1634
	Examiner Name	A. Chakrabarti
	Title: High Throughput Transcriptome and Functional Validation Analysis	

Sir:

Prior to Applicants' telephone conference with the Examiner on May 29, 2003, Applicants would like to provide the Examiner with the attached review (from Kimball's Biology Pages), which briefly summarizes the use of antisense RNA, which is a single stranded molecule complementary to an mRNA; and RNAi, which is a double stranded molecule.

Also attached is a review of RNAi, which discusses, in accordance with Applicants prior response, the effect of double-stranded RNA in triggering an interferon response in mammalian cells (see Figure 3).

If the Examiner finds that a Telephone Conference would expedite the prosecution of this application, he is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number AGYT-013CIP.

Respectfully submitted,

Date: May 28, 2003

By: Pamela Sherwood

Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Antisense RNA



Messenger RNA (mRNA) is single-stranded. Its sequence of nucleotides is called "sense" because it results in a gene product (protein). Normally, its unpaired nucleotides are "read" by transfer RNA anticodons as the ribosome proceeds to translate the message.

5' ...A T G G C C T G G A C T T C A... 3' Sense strand of DNA
3' ...T A C C G G A C C T G A A G T... 5' Antisense strand of DNA

↓ Transcription of antisense strand

5' ...A U G G C C U G G A C U U C A... 3' mRNA

↓ Translation of mRNA

Met — Ala — Trp — Thr — Ser — Peptide

However, RNA can form duplexes just as DNA does. All that is needed is a second strand of RNA whose sequence of bases is complementary to the first strand; e.g.,

5' C A U G 3' mRNA
3' G U A C 5' Antisense RNA

The second strand is called the antisense strand because its sequence of nucleotides is the complement of message sense. When mRNA forms a duplex with a complementary antisense RNA sequence, translation is blocked. This may occur because the ribosome cannot gain access to the nucleotides in the mRNA or duplex RNA is quickly degraded by ribonucleases in the cell.

With recombinant DNA methods, synthetic genes (DNA) encoding antisense RNA molecules can be introduced into the organism.

Example: the Flavr Savr tomato. Most tomatoes that have to be shipped to market are harvested before they are ripe. Otherwise, enzymes synthesized by the tomato cause them to

spoil before they reach the customer.

Transgenic tomatoes have been constructed that carry in their genome an artificial gene (DNA) that is transcribed into an antisense RNA complementary to the mRNA for an enzyme involved in spoilage. These tomatoes make only 10% of the normal amount of the enzyme. The goal of this work was to provide supermarket tomatoes with something closer to the appearance and taste of tomatoes harvested when ripe.

Antisense RNA for human therapy. Antisense RNA that is complementary to the proto-oncogene BCL-2 is being examined as a possible therapy for certain B-cell lymphomas and leukemias. Antisense oligodeoxynucleotides (ODNs) are synthetic molecules that - because they, too, are antisense - also block mRNA translation. One has been approved for human therapy

Antisense RNA also occurs naturally. Do cells contain genes that are naturally translated into antisense RNA molecules capable of blocking the translation of other genes in the cell? Recently a few cases have been found and these seem to represent another method of regulating gene expression.

In both mice and humans, the gene for the insulin-like growth factor 2 receptor (Igf2r) that is inherited from the father synthesizes an antisense RNA that appears to block synthesis of the mRNA for Igf2r. An inherited difference in the expression of a gene depending on whether it is inherited from the mother or the father is called genomic or parental imprinting.

RNA interference (RNAi)

In testing the effects of antisense RNA, one should use sense RNA of the same coding region as a control. Surprisingly, preparations of sense RNA often turn out to be as effective an inhibitor as antisense RNA.

Why? It seems that the preparations of sense RNA often are contaminated with hybrids: **sense and antisense strands that form a double helix of double-stranded RNA (dsRNA)**. Double-stranded RNA corresponding to a particular gene is a powerful suppressant of that gene. In fact, the suppressive effect of antisense RNA probably also depends on its ability to form dsRNA (using the corresponding mRNA as a template).

The ability of dsRNA to suppress the expression of a gene corresponding to its own sequence is called RNA interference (RNAi). It is also called post-transcriptional gene silencing or PTGS.

Mechanism of RNAi. The only RNA molecules normally found in the cytoplasm of a cell are molecules of single-stranded mRNA. If the cell finds molecules of double-stranded RNA dsRNA, it uses an enzyme (the one in Drosophila has been named Dicer) to cut them into fragments containing 21-25 base pairs (~ 2 turns of a double helix).

The two strands of each fragment then separate enough to expose the antisense strand so that it can bind to the complementary sense sequence on a molecule of mRNA. This triggers cutting the mRNA in that region thus destroying its ability to be translated into a polypeptide. Because of their action, these fragments of RNA have been named "short (or small) interfering RNA" (siRNA).

RNAi has been found to operate in such diverse organisms as plants, fungi, and animals such as Drosophila, C. elegans, and even mice and the zebrafish. Such a universal cell response must have an important function What could it be?

One possibility. The viruses of both plants and animals have a genome of dsRNA. And many other viruses of both plants and animals have an RNA genome that in the host cell is briefly converted into dsRNA. So RNAi may be a weapon to counter infections by these viruses by destroying their mRNAs and thus blocking the synthesis of essential viral proteins.

Another possibility. In C. elegans, successful development through its larval stages and on to the adult requires the presence of at least two "small temporal RNAs" ("stRNAs")- single-stranded RNA molecules containing about 22 nucleotides - thus the same size as the fragments made by the Drosophila Dicer gene. These small transcripts are generated by the cleavage of larger precursors using the C. elegans version of Dicer. They act by inhibiting translation of several messenger RNAs in the worm (by binding to a region of complementary sequence in the 3' untranslated region [3'UTR] of the mRNA). So RNA interference may be the unexpected dividend of a another basic process of controlling gene expression.

RNAi as a tool. In any case, the discovery of RNAi adds a promising tool to the toolbox of molecular biologists. Introducing dsRNA corresponding to a particular gene will knock out the cell's own expression of that gene.

RNAi : the review

Most readers of this article are not familiar with RNA interference or may even have never heard about this new powerful technology. In a few chapters, this review will guide you step-by-step towards a better understanding of what is RNA interference, how does it work, what should be done, and what should be avoided. With our help, you will discover a new fascinating world: gene suppression through small RNA molecules.

Establishing a convenient and reliable method to knock-out gene expression at the mRNA level has been the dream and nightmare of molecular biologists for the last 15 years. In efforts to generate loss-of function cells or organisms, various molecules that included, for example, antisense sequences, ribozymes, and chimeric oligonucleotides have been tested, but the design of such molecules was based on trial and error, depending on the properties of the target gene. Moreover, the desired effects were difficult to predict, and often only weak suppression achieved (Braasch and Corey, 2002).

More than a decade ago, some botanists won the jackpot unconsciously. In 1990, two teams lead respectively by Napoli and Stuitje first reported the co-suppression of an overexpressed *chalcone synthase* (CHS) in plants. When trying to create more purple petunias, they sometimes achieved an unexpected opposite result (more white petunias!) The mechanism of this curious phenomenon remained a mystery, but it was proposed that the products of degradation of the double-stranded RNA region in the CHS gene might be related to this post-transcriptional gene silencing (PTGS) (Van der Krol et al., 1990 ; Jorgensen et al., 1996) (Table 1).

In the fungi *Neurospora crassa*, it was shown that an overexpressed transgene can also induce gene silencing at the post-transcriptional level, a phenomenon referred to as quelling (Romano and Macino, 1992) (Table 1).

In 1998, building on these previous studies, Andy Fire of the Carnegie Institute and Craig Mello of the University of Massachusetts for the first time demonstrated with the worm *Caenorhabditis elegans* that dsRNA (double-stranded RNA) may specifically and selectively inhibit the gene expression in an extremely efficient manner. In their experiment, the sequence of the first strand (the so-called sense RNA) coincides with that of the corresponding region of the target messenger RNA (mRNA). The second strand (*antisense* RNA) is complementary to this mRNA. The resulting dsRNA turned out to be far more (several orders of magnitude) efficient

than the corresponding single-stranded RNA molecules (in particular, *antisense* RNA). Fire et al., 1998 named the phenomenon RNAi for RNA *interference*. This powerful gene silencing mechanism has been shown to operate in several species among most phylogenetic phyla (Table 2).

Table 1: Post-transcriptional gene silencing mechanisms

Phylum	Species	Mechanism	Effector	Reference
Fungi	Neurospora	quelling	Transgenes	Cogoni and Macino, 1997
Plants	Arabidopsis	PTGS	Transgenes	Elmayan et al., 1998
	Petunia			Dehio and Schell, 1994
	Mammals	Transcriptional gene silencing	Transgenes, virus	Fulmer et al., 1995
Invertebrates	C. elegans	RNAi	dsRNA	Kennedy et al., 1998
		Transcriptional gene silencing	Transgenes	Kelly and Fire, 1998
	Drosophila	RNAi	dsRNA	Misquitta and Patterson, 1999
			siRNA	Fagegaltier et al., 2002
		co-suppression	Transgenes	Fulbright et al., 1999
	Paramecium	Homology-dependent silencing	Transgenes	Ruiz et al., 1998
	Trypanosoma	RNAi	dsRNA	Wang et al., 2000
Vertebrates	Danio rerio	RNAi	dsRNA	Wargelius et al., 1999
	Mus musculus	RNAi	dsRNA	Wianny and Zernicka-Goetz, 2000

Table 2: Examples of RNAi in several species

Species		References
Caenorhabditis elegans	Nematode	Fire et al., 1998; Tavernarakis et al., 2000
Danio rerio	Teleostei	Wargelius et al., 1999
Trypanosoma brucei	Diplozoa	Wang et al., 2000
Hydra magnipapillata	Cnidaria	Lohmann et al., 1999
Schistosoma mediterranea	Platelmia	Boroviak and Newmark, 1996
Escherichia coli	Bacteria	Yoshikawa et al., 2000
Neurospora crassa	Fungus	Cogoni and Macino, 1999
Drosophila melanogaster	Diptera	Kennerdell et al., 2001
Mus musculus	Mammals	Wianny and Zernicka-Goetz, 1999
Arabidopsis thaliana	Plants	Dalmay et al., 2001

RNAi begins when an enzyme, which Hannon and colleague Emily Bernstein discovered and named DICER, encounters dsRNA and chops it into pieces called small-interfering RNAs or siRNAs. This protein belongs to the RNase III nuclease family. A complex of proteins gathers up these RNA remains and uses their code as a guide to search out and destroy any RNAs in the cell with a matching sequence, such as target mRNA (for review see Bosher and Labouesse, 2000).

Figure 1 depicts an updated model of the RNAi phenomenon (Akashi et al., 2001; Willecke et al., 2002). In this model, the initiator event coincides with the appearance in a cell of transgenes, transposons, virus, dsRNA or aberrant single-stranded RNA. In the latter case, as described for quelling, RNA-dependent RNA Polymerase (RdRP) is responsible for the production of dsRNA. The following steps might be summarized as follows:



Figure 1. RNAi hypothetical model

- Step 1: dsRNA recognition and scanning process.
- Step 2: dsRNA cleavage through RNase III activity and production of siRNAs.
- Step 3: association of the siRNAs and associated factors in RISC complexes.
- Step 4: recognition of the complementary target mRNA.
- Step 5: cleavage of the target mRNA in the center of the region complementary to the siRNA (see yellow triangle).
- Step 6: degradation of the target mRNA and recycling of the RISC complex (see figure 2).



Figure 2. RISC complex hypothetical model

RNAi is extremely active in several invertebrate species. Therefore, it was highly tempting to adapt this technology to mammals. However, mammalian cells have developed various protective phenomena against viral infections that could impede the use of this approach. Indeed, the presence of extremely low levels of viral dsRNA triggers an interferon response (called "acute-phase response") and the activation of a dsRNA Responsive Protein Kinase (PKR). PKR phosphorylates and inactivates translation factor Elf2α leading to activation of the 2', 5' oligoadenylate synthetase, finally resulting in RNAse L activation. This cascade induces a global non-specific suppression of translation, which in turn triggers apoptosis (for review see Williams, 1997; Gil and Esteban, 2000)



Figure 3: Non-specific and specific dsRNA silencing pathways

In 2000, a first attempt was made with dsRNA in mouse embryos. Wianny and Zernicka-Goetz have shown that injected dsRNA specifically inhibit 3 genes (MmGFP under the control of the Elongation Factor 1a, E-cadherin, and cenos) in the mouse oocyte and early embryo. Translational arrest, and thus a PKR response, was not observed as the embryos continued to develop

However, we had to wait another year before covering the decisive step. Procedures developed by *Ribopharma AG* (Kulmbach, Germany) (and for which a patent has been granted) first demonstrated the functionality of RNAi in

mammalian cells. *Ribopharma's* researchers reasoned that smaller dsRNA, similar to those produced by DICER, should not trigger cell death. This proved to be correct and by using short (20-24 base pairs) dsRNAs - which are called *SIRPLEX™* in *Ribopharma's* terminology – they specifically switched off genes even in human cells without initiating the acute-phase response. Thus, *SIRPLEX™* is suitable for gene target validation and therapeutic applications in many species, including humans. Similar experiments carried out later by other research groups (Elbashir et al., 2001; Caplen et al., 2001) further confirmed these results. From that date, small dsRNA, called siRNA for small interfering RNAs, become the preferred RNAi effector in many laboratories.

Driven in part by their desire for an alternative to siRNAs, Paddison et al. (2002) tried to use small RNAs folded in hairpin structures to inhibit the function of specific genes. This work was inspired by previous studies showing that some genes in *Caenorhabditis elegans* naturally regulate other genes through RNAi by coding for hairpin-structured RNAs. Tested in a variety of normal and cancer human and mouse cell lines, short hairpin RNAs (shRNAs) are able to silence genes as efficiently as their siRNA counterparts. Moreover, shRNAs exhibits better reassociation kinetics *in vivo* than equivalent duplexes. Even more important, these authors generated transgenic cell lines engineered to synthesize shRNAs that exhibit a long-lasting silencing effect throughout cell divisions. It should be noted that Eurogentec's RNA synthesis platform represents the first commercial source of shRNAs.

Recently, another group of small RNAs (also comprised in the range of 21-25 nt) was shown to mediate downregulation of gene expression. These RNAs, known as small temporally regulated RNAs (stRNAs), have been described in *Caenorhabditis elegans* were they regulate timing of gene expression during development. It should be noted that stRNAs and siRNAs, despite obvious similarities, proceed through different modes of action (for review see Banerjee and Slack, 2002). In contrast with siRNAs, 22 nt long stRNAs downregulate expression of target mRNA after translational initiation without affecting mRNA integrity. Recent studies indicate that the two stRNAs first described in nematods are the members of a huge family with hundreds of additional micro-RNAs (miRNAs) existing in metazoans (Grosshans and Slack, 2002).

Scientists have initially used RNAi in several systems, including *Caenorhabditis elegans*, Drosophila, trypanosomes, and various other invertebrates. Moreover, using this approach, several groups have recently presented the specific suppression of protein biosynthesis in different mammalian cell lines - specifically in HeLa cells - showing that RNAi is a broadly applicable method for gene silencing in vitro. Based on these results, RNAi has rapidly become a well-recognized tool for validating (identifying and assigning) gene functions. With the increasing importance of Proteomics it will rapidly gain credit. RNA interference employing short dsRNA oligonucleotides will, moreover,

permit to decipher the function of genes being only partially sequenced.

RNAi will therefore become inevitable in studies such as :

- Inhibition of gene expression at the post-transcriptional level in eucaryotic cells. In this context, RNAi is a straightforward tool to rapidly assess gene function and reveal null phenotypes.
- Development of the RNAi technology for use in post-implantation embryos.
- The predominant economic significance of RNA interference is established by its application as a therapeutic principle. As so, RNAi may yield RNA-based drugs to treat human diseases.

In 1999, Tuschl et al. have deciphered the silencing effect of siRNAs showing that their efficiency is a function of the length of the duplex, the length of the 3'-end overhangs, and the sequence in these overhangs.

Based on this founder work, Eurogentec recommends that the target mRNA region, and hence the sequence of the siRNA duplex, should be chosen using the following guidelines :

- Since RNAi relies on the establishment of complex protein interactions, it is obvious that the mRNA target should be devoided of unrelated bound factors. In this context, both the 5' and 3' untranslated regions (UTRs) and regions close to the start codon should be avoided as they may be richer in regulatory protein binding sites.
- The sequence of the siRNA is therefore selected as follows :
  - In your mRNA sequence, select a region located 50 to 100 nt downstream of the AUG start codon.
  - In this region, search for the following sequences: AA(N19)TT or AA(N21). Calculate the G/C percentage for each sequence identified. Ideally, the G/C content is 50 % but it must less than 70 % and greater than 30 %.
  - Perform a BLAST (i.e. NCBI ESTs database) with the nucleotide sequence fitting best the previous criteria to ensure that only one gene will be inactivated.
  - Don't pay too much attention to the secondary structure of the target mRNA since it does not have a strong effect on the observed silencing effect.

The selection process is that simple and proved its efficiency in numerous studies!

In collaboration with leading authorities in the field of antisense studies, Eurogentec has selected from the literature a set of validated siRNA sequences. A comprehensive list of the corresponding target genes is given in Table 3. These genes may serve as positive controls. More information about these genes is available upon request.

Table 3: Validated siRNAs available from Eurogentec

Gene name	Species	Gene name	Species
Beta-actin	Human	Keratin 18	Human
Gamma-actin	Human	Lamins A/C, B1, B2	Human
ARC21	Human	[illegible]	Human
ATR binding protein	Human	[illegible]	Human
LAP-2	Human	[illegible]	Human
NIMA	Human	Cyclin B1	Xenopus laevis
cdk1	Human	Cyclin B2	Xenopus laevis
CENP-E	Human	[illegible]	Mouse
Dynein 1 heavy chain	Human	Zyxin	Mouse
Eg-5	Human	GFP	Jellyfish
Emerin	Human	CAT	Bacteria
GAS41	Human	Luciferases GL2, GL3	Firefly

Every researcher would tell it: "*The choice of the right controls makes the whole difference between a good and a bad experiment*". This adage is particularly true for RNAi studies.

Therefore, to maximize your result interpretation, the following precautions should be taken when using siRNAs:

- Always test the sense and antisense single strands in separate experiments.
- Try to use a scramble siRNA duplex. This should have the same nucleotide composition as your siRNA but lack significant sequence homology to any other gene (including yours).
- If possible, knock-down your gene with two independent siRNA duplexes to control the specificity of the silencing process.

An annealing step is necessary when working with single-stranded RNA molecules. It is critical that all handling steps be conducted under sterile, RNase-free conditions.

To anneal the RNAs, the oligos must first be quantified by UV absorption at 260 nanometers (nm). RNAs ordered from Eurogentec are always quantified with the highest accuracy. The following protocol based on Elbashir et al. (2001) is then used for annealing :

- Separately aliquot and dilute each RNA oligo to a concentration of 50 µM.
- Combine 30 µl of each RNA oligo solution and 15 µl of 5X annealing buffer. Final buffer concentration is: 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate. Final volume is 75 µl.
- Incubate the solution for 1 minute at 90 °C, centrifuge the tube for 15 seconds, let sit for 1 hour at 37 °C, then use at ambient temperature. The solution can be stored frozen at -20 °C and freeze-thawed up to 5 times. The final concentration of siRNA duplex is usually 20 µMolar.

Despite its extreme efficiency, the selected siRNA might not work in your cell system. If so, it is advisable to check the following points :

• If no knock-out of the target gene is observed, it may be useful to analyze whether the corresponding mRNA was effectively degraded upon addition of the siRNA. Two or three days after transfection, the total RNA is extracted and subjected to further analysis. RT/PCR appears to be the method of choice since it is faster and far more sensitive than Northern blotting.

• Check for any sequencing error or polymorphism in your target gene. It has been shown that a single base mutation in the pairing region of the siRNA duplex is sufficient to abolish RNAi.

• Check that your cell line can effectively express the target mRNA.

Eurogentec's siRNAs are usually synthetized at the 0.2 or 1 µmol scale. You might receive them either highly pure (>95%) or simply crude with their protective groups still attached (> 80% purity).

By default, we propose dTdT overhangs at the 3' ends, which typically provide more reliable synthesis and stability than UU. However, you may specify any mixture of DNA and RNA bases to fit your experimental requirements.

Finally, Eurogentec proposes more than 10 chemical modifications allowing the fanciest experiments (Table 4).

RNAs are famous for their ability to form stable secondary structures. Based on this observation, Eurogentec's siRNA oligonucleotides are proposed PAGE purified, the best purification method to remove all but full-length synthesis products.

Eurogentec has been at the leading edge of the QC methods, introducing Mass Spectrometry MALDI-TOF Quality Control in 1999.

When you order one of our siRNA sets, you receive single-strand siRNAs in separate tubes either lyophilized (PAGE purified) or in solution (crude). Such conditioning may seem bothering but it has several key advantages by allowing you

- to use each single oligo as a negative control.
- to test various combinations of modified strands.

It is clear : RNAi is a powerful method. However, as any other antisense technology, this must be handled and interpreted with great care. Inevitably negative controls will represent unpleasant extra costs. In this context, Eurogentec has decided to propose affordable high-quality siRNAs so that well-controlled RNAi experiments will become feasible even in small labs.

Table 4: Modifications available for siRNA

LABELLED siRNA

Modification	Reference
5' HEX / TET	OR-0030-M10/M100
5' Fluorescein, 6-FAM	OR-0030-M10/6FAM
Fluorescein, 3' internal	OR-0030-M10/I-FLUO
3' Fluorescein, 6-FAM	OR-0030-M10/6FAM
5' TAMRA, Rhodamine	OR-0030-M10/5TAMRA
3' TAMRA, Rhodamine	OR-0030-M10/3TAMRA
5' Biotynate	OR-0030-M10/BIOT

If you can't find your particular modification, please don't hesitate to contact us

SEE
www.eurogentec.com
siRNA chapter

Contact our Customer Helpdesk
Tel : +32 4 240 76 76 - Fax : +32 4 264 07 88 - info@eurogentec.com

Product manager: D. Poncelet Tel. : +32 4 366 61 58
d.poncelet@eurogentec.com

Akashi H, Miyagishi M, Taira K. Suppression of gene expression by RNA interference in cultured plant cells. Antisense Nucleic Acid Drug Dev. 2001, 11(6):359-67

Alvarado A.S., and Newmark P.A. Double-stranded RNA specifically disrupts gene expression during planarian regeneration. Proc. Natl. Acad. Sci. USA 1999. 96, 5049-54

Banerjee D, Slack F. Control of developmental timing by small temporal RNAs: a paradigm for RNA-mediated regulation of gene expression. Bioessays. 2002, 24(2):119-29

Bernstein E, Denli AM, Hannon GJ. The rest is silence. RNA. 2001, 7(11):1509-21

Bosher JM, Labouesse M. RNA interference: genetic wand and genetic watchdog. Nat Cell Biol. 2000, 2(2):E31-6

Braasch DA, Corey DR. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry. 2002, 41(14):4503-10

Caplen, N.J., Parrish, S., Imani, F., Fire, A. & Morgan, R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA. 2001, 98, 9742-9747

Cogoni C, Macino G. Homology-dependent gene silencing in plants and fungi: a number of variations on the same theme. Curr Opin Microbiol. 1999, 2(6):657-62

Dehio C, Schell J. Identification of plant genetic loci involved in a posttranscriptional mechanism for meiotically reversible transgene silencing. Proc Natl Acad Sci U S A. 1994, 91(12):5538-42

Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15(2):188-200

Elmayan T, Balzergue S, Beon F, Bourdon V, Daubremet J, Guenet Y, Mourrain P, Palauqui JC, Vernhettes S, Vialle T, Wostrikoff K, Vaucheret H. Arabidopsis mutants impaired in cosuppression. Plant Cell. 1998, 10(10):1747-58

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998, 391(6669):806-11

Furner IJ, Sheikh MA, Collett CE. Gene silencing and homology-dependent gene silencing in Arabidopsis: genetic modifiers and DNA methylation. Genetics. 1998, 149(2):651-62

Gil J, Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis. 2000, 5(2):107-14

Grosshans H, Slack FJ. Micro-RNAs: small is plentiful. J Cell Biol. 2002, 156(1):17-21

Jorgensen RA, Cluster PD, English J, Que Q, Napoli CA. Chalcone synthase cosuppression phenotypes in petunia flowers: comparison of sense vs. antisense constructs and single-copy vs. complex T-DNA sequences. Plant Mol Biol. 1996, 31(5):957-73

Kelly WG, Fire A. Chromatin silencing and the maintenance of a functional germline in Caenorhabditis elegans. Development. 1998, 125(13):2451-6

Ketting RF, Haverkamp TH, van Luenen HG, Plasterk RH. Mut-7 of C. elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD. Cell. 1999, 99(2):133-41

Lohmann JU, Endl I, Bosch TC. Silencing of developmental genes in Hydra. Dev Biol. 1999, 214(1):211-4

Misquitta L, Paterson BM. Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): a role for nautilus in embryonic somatic muscle formation. Proc Natl Acad Sci U S A. 1999, 96(4):1451-6

Newmark PA, Alvarado AS. Not your father's planarian: a classic model enters the era of functional genomics. Nat Rev Genet. 2002, 3(3):210-9

Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002, 16(8):948-58

Pal-Bhadra M, Bhadra U, Birchler JA. Role of multiple trans-acting regulators in modifying the effect of a [illegible] on host gene expression in Drosophila. Mol Gen Genet. 1998, 259(2):198-206

Romano N, Macino G. Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol Microbiol. 1992, 6(22):3343-53

Ruiz F, Vayssie L, Klotz C, Sperling L, Madeddu L. Homology-dependent gene silencing in Paramecium. Mol Biol Cell. 1998, 9(4):931-43

Tavernarakis N, Wang SL, Dorovkov M, Ryazanov A, Driscoll M. Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes. Nat Genet. 2000, 24(2):180-3

Tchurikov NA, Chistyakova LG, Zavilgelsky GB, Manukhov IV, Chernov BK, Golova YB. Gene-specific silencing by expression of parallel complementary RNA in Escherichia coli. J Biol Chem. 2000, 275(34):26523-9

Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 1999, 13(24):3191-7

van der Krol AR, Mur LA, Beld M, Mol JN, Stuitje AR. Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell. 1990, 2(4):291-9

Wang Z, Morris JC, Drew ME, Englund PT. Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters. J Biol Chem. 2000, 275(51):40174-9

Wargelius A, Ellingsen S, Fjose A. Double-stranded RNA induces specific developmental defects in zebrafish embryos. Biochem Biophys Res Commun. 1999, 263(1):156-61

Wianny F, Zernicka-Goetz M. Specific interference with gene function by double-stranded RNA in early mouse development. Nat Cell Biol. 2000, 2(2):70-5

Wiedeke et al. 2002 http://www.[illegible]/C_[illegible].pdf

Williams BR. Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochem Soc Trans. 1997, 25(2):509-13